This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: ENGAGE-AF TIMI

Novel oral anticoagulants in daily clinical practice – German experience with rivaroxaban

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

Novel oral anticoagulants in daily clinical practice – German experience with rivaroxaban

Ingo Ahrens, Christoph Bode

Abstract

Summary Oral anticoagulation has been restricted to vitamin K antagonists (VKAs) for more than 50 years. Starting in the last decade of the past century, central coagulation factors such as thrombin and factor Xa were explored as potential targets for the development of novel oral anticoagulants (NOACs). This led to the successful development and approval of a novel class of direct oral anticoagulants targeting factor Xa. Rivaroxaban was the first of the novel class of agents named ‘xabans’ that are direct oral factor Xa inhibitors. Since its initial approval for thromboembolic prophylaxis after hip and knee surgery in 2008, rivaroxaban a

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now